Implications of ADAM17 Activation for Hyperglycaemia, Obesity and Type 2 Diabetes

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2021 Apr 27

PMID 33904577

Citations 14

Authors

Jennifer Matthews

Sofia Villescas

Lakshini Herat

Markus Schlaich

Vance Matthews

Affiliations

Soon will be listed here.

Abstract

In this review, we focus specifically on the role that the metalloproteinase, A Disintegrin and Metalloproteinase 17 [ADAM17] plays in the development and progression of the metabolic syndrome. There is a well-recognised link between the ADAM17 substrate tumour necrosis factor α (TNF-α) and obesity, inflammation and diabetes. In addition, knocking out ADAM17 in mice leads to an extremely lean phenotype. Importantly, ADAM17-deficient mice exhibit one of the most pronounced examples of hypermetabolism in rodents to date. It is vital to further understand the mechanistic role that ADAM17 plays in the metabolic syndrome. Such studies will demonstrate that ADAM17 is a valuable therapeutic target to treat obesity and diabetes.

Citing Articles

Obesity and Adipose-Derived Extracellular Vesicles: Implications for Metabolic Regulation and Disease.

Malaguarnera M, Cauli O, Cabrera-Pastor A Biomolecules. 2025; 15(2).

PMID: 40001534 PMC: 11853251. DOI: 10.3390/biom15020231.

Relationship Between Systemic Inflammatory Response Exponents, Levels of ADAM10, ADAM17 Proteins and Selected Clinical Parameters in Patients with Colorectal Cancer: Original Research Study.

Sikora-Skrabaka M, Walkiewicz K, Waniczek D, Strzelczyk J, Nowakowska-Zajdel E Int J Mol Sci. 2025; 26(3).

PMID: 39940871 PMC: 11817235. DOI: 10.3390/ijms26031104.

Expression of sPD-L1 levels in an ex vivo liver perfusion model.

Irsara C, Weissenbacher A, Krendl F, Anliker M, Hofmann J, Hautz T Clin Exp Immunol. 2024; 219(1).

PMID: 39435859 PMC: 11773811. DOI: 10.1093/cei/uxae094.

Multi-Omics Analysis Revealed the rSNPs Potentially Involved in T2DM Pathogenic Mechanism and Metformin Response.

Damarov I, Korbolina E, Rykova E, Merkulova T Int J Mol Sci. 2024; 25(17).

PMID: 39273245 PMC: 11394919. DOI: 10.3390/ijms25179297.

Potential Effects of Hyperglycemia on SARS-CoV-2 Entry Mechanisms in Pancreatic Beta Cells.

Michaels T, Essop M, Joseph D Viruses. 2024; 16(8).

PMID: 39205219 PMC: 11358987. DOI: 10.3390/v16081243.

References

Qian M, Bai S, Brogdon B, Wu J, Liu R, Covington M . Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme.... Drug Metab Dispos. 2007; 35(10):1916-25. DOI: 10.1124/dmd.107.015933. View

Herat L, Rudnicka C, Okada Y, Mochizuki S, Schlaich M, Matthews V . The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice. Int J Mol Sci. 2017; 18(4). PMC: 5412464. DOI: 10.3390/ijms18040884. View

Moss M, Minond D . Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. Mediators Inflamm. 2017; 2017:9673537. PMC: 5688260. DOI: 10.1155/2017/9673537. View

Condon T, Flournoy S, Sawyer G, Baker B, Kishimoto T, Bennett C . ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes. Antisense Nucleic Acid Drug Dev. 2001; 11(2):107-16. DOI: 10.1089/108729001750171353. View

Sharma A, Bender S, Zimmermann M, Riesterer O, Broggini-Tenzer A, Pruschy M . Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer. Clin Cancer Res. 2016; 22(17):4428-39. DOI: 10.1158/1078-0432.CCR-15-2449. View

Serino M, Menghini R, Fiorentino L, Amoruso R, Mauriello A, Lauro D . Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes. 2007; 56(10):2541-6. DOI: 10.2337/db07-0360. View

Perrier S, Darakhshan F, Hajduch E . IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?. FEBS Lett. 2006; 580(27):6289-94. DOI: 10.1016/j.febslet.2006.10.061. View

Palau V, Pascual J, Soler M, Riera M . Role of ADAM17 in kidney disease. Am J Physiol Renal Physiol. 2019; 317(2):F333-F342. DOI: 10.1152/ajprenal.00625.2018. View

Hedemann N, Rogmans C, Sebens S, Wesch D, Reichert M, Schmidt-Arras D . ADAM17 inhibition enhances platinum efficiency in ovarian cancer. Oncotarget. 2018; 9(22):16043-16058. PMC: 5882316. DOI: 10.18632/oncotarget.24682. View

10.

Sommer A, Kordowski F, Buch J, Maretzky T, Evers A, Andra J . Phosphatidylserine exposure is required for ADAM17 sheddase function. Nat Commun. 2016; 7:11523. PMC: 4866515. DOI: 10.1038/ncomms11523. View

11.

Black R, Rauch C, Kozlosky C, Peschon J, Slack J, Wolfson M . A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997; 385(6618):729-33. DOI: 10.1038/385729a0. View

12.

Kefaloyianni E, Muthu M, Kaeppler J, Sun X, Sabbisetti V, Chalaris A . ADAM17 substrate release in proximal tubule drives kidney fibrosis. JCI Insight. 2016; 1(13). PMC: 5026414. DOI: 10.1172/jci.insight.87023. View

13.

Hirode G, Wong R . Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016. JAMA. 2020; 323(24):2526-2528. PMC: 7312413. DOI: 10.1001/jama.2020.4501. View

14.

Jowett J, Okada Y, Leedman P, Curran J, Johnson M, Moses E . ADAM28 is elevated in humans with the metabolic syndrome and is a novel sheddase of human tumour necrosis factor-α. Immunol Cell Biol. 2012; 90(10):966-73. PMC: 3837706. DOI: 10.1038/icb.2012.44. View

15.

Pennica D, Lam V, Mize N, WEBER R, Lewis M, Fendly B . Biochemical properties of the 75-kDa tumor necrosis factor receptor. Characterization of ligand binding, internalization, and receptor phosphorylation. J Biol Chem. 1992; 267(29):21172-8. View

16.

Gonzalez L, Garrie K, Turner M . Type 2 diabetes - An autoinflammatory disease driven by metabolic stress. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(11):3805-3823. DOI: 10.1016/j.bbadis.2018.08.034. View

17.

Li Z, Li Y, Overstreet J, Chung S, Niu A, Fan X . Inhibition of Epidermal Growth Factor Receptor Activation Is Associated With Improved Diabetic Nephropathy and Insulin Resistance in Type 2 Diabetes. Diabetes. 2018; 67(9):1847-1857. PMC: 6110321. DOI: 10.2337/db17-1513. View

18.

Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J, Turner A . Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020; 126(10):1456-1474. PMC: 7188049. DOI: 10.1161/CIRCRESAHA.120.317015. View

19.

Kraakman M, Kammoun H, Allen T, Deswaerte V, Henstridge D, Estevez E . Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 2015; 21(3):403-16. DOI: 10.1016/j.cmet.2015.02.006. View

20.

Wang Y, Herrera A, Li Y, Belani K, Walcheck B . Regulation of mature ADAM17 by redox agents for L-selectin shedding. J Immunol. 2009; 182(4):2449-57. PMC: 2653275. DOI: 10.4049/jimmunol.0802770. View